FDA revises warnings for anemia drugs
The Food and Drug Administration recently revised boxed warnings and other labeling changes for drugs that treat certain types of anemia.The warnings and label changes address the risks that the drugs pose to patients with cancer and patients with chronic kidney failures. They also include a statement that the drugs do not necessarily improve symptoms of anemia, fatigue and quality of life in cancer patients.
The three anti-anemia drugs approved by the FDA are Aranesp, Epogen and Procrit. All are manufactured by Amgen Inc. of Thousand Oaks, CA.